Merck to Present New Data on ZEPATIER ™ (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting® 2016

Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company ’s chronic hepatitis C virus (HCV) clinical development programs will be presented atThe Liver Meeting® 2016. Fifteen scientific abstracts, including seven oral and eight poster presentations, will highlight findings from Merck ’s HCV clinical development programs.Language: EnglishContact: MerckMedia:Doris Li, 908-740-1903Ian McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News Source Type: news